Use of noben (idebenone) in the treatment of dementia and memory impairments without dementia

Neuroscience and Behavioral Physiology

Volumn 39, Issue 5, 2009, Pages 501-506

  Voronkova, K V ^a,b   Meleshkov, M N ^a,b  

^a PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^b Litfond Clinic   (Russian Federation)

Author keywords

Cognitive disorders; Dementia; Neuropsychological investigations; Noben(idebenone); Treatment

Indexed keywords

IDEBENONE; NOBEN; NOOTROPIC AGENT; UNCLASSIFIED DRUG; VASOACTIVE AGENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; ATTENTION; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DEMENTIA; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FEMALE; HUMAN; KINESTHESIA; MALE; MEMORY DISORDER; MENTAL PERFORMANCE; MINI MENTAL STATE EXAMINATION; NAUSEA; NEUROPSYCHOLOGICAL TEST; QUALITY OF LIFE; SPEECH AND LANGUAGE;

AGED; AGED, 80 AND OVER; ANTIOXIDANTS; ATTENTION; COGNITION; COGNITION DISORDERS; DEMENTIA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEMORY; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; UBIQUINONE;

EID: 67349242316     PISSN: 00970549     EISSN: 1573899X     Source Type: Journal    
DOI: 10.1007/s11055-009-9148-0     Document Type: Article

References (24)

1. S. I. Gavrilov and G. A. Zharikov, "Galantamine (reminil) in the treatment of Alzheimer's disease and vascular dementia," Zh. Nevrol. Psikhiatr., 12, 59-65 (2003).
2. S. I. Gavrilov, "Alzheimer's disease: Diagnosis and treatment," Vrach, 6, 1-4 (2004).
3. S. N. Illarioshkin et al., Inherited Ataxias and Paraplegias [in Russian], Medpress-Inform, Moscow (2006), p. 415.
4. V. N. Krasnov, A. P. Myzychenko, et al., "The new neurometabolic cerebroprotector idebenone: Potential for use in psychiatry," Sots. Klin. Psikhiatr., 1, 61-63 (2000).
5. R. Artuch, et al., "Friedreich's ataxia: Idebenone treatment in early stage patients," Neuropediatrics, 33, No. 4, 190-193 (2002).
6. B. Bergamasco, et al., "Effects of idebenone in elderly subjects with cognitive decline. Results of a multicentre clinical trial," Arch. Gerontol. Geriatr., 15, No. 3, 279-286 (1992).
7. B. Bergamasco, et al., "Idebenone, a new drug in the treatment of cognitive impairment in patients with dementia of the Alzheimer type," Funct. Neurobiol., 9, No. 3, 161-168 (1994).
8. G. Buyse et al., "Idebenone treatment in Friedreich's ataxia: neurological, cardiac, and biochemical monitoring," Neurobiology, 60, 1679-1681 (2003).
9. T. Erkinjuntti, G. Roman, and S. Gauthier, "Treatment of vascular dementia evidence from clinical trials with cholinesterase inhibitors," J. Neurol. Sci., 226, No. 1-2, 63-66 (2004).
10. J. G. Evans, G. Wilcock, and J. Birks, "Evidence-based pharmacotherapy of Alzheimer's disease," Int. J. Neuropsychopharmacol., 7, No. 3, 351-369 (2004).
11. V. Geromel, N. Darin, D. Chretien, et al., "Coenzyme Q and idebenone in the therapy of respiratory chain diseases: Rationale and comparative benefits," Molec. Genet. Metab., 77, 21-30 (2002).
12. H. Gutzmann et al., "Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: Results of a randomized, double-blind, parallel-group multicenter study," Pharmacopsychiatry, 35, 12-18 (2002).
13. N. L. Keltner, A. L. Zielinski, and M. S. Hardin, "Drugs used for cognitive symptoms of Alzheimer's disease," Perspect. Psychiatr. Care, 37, No. 1, 31-34 (2001).
14. D. H. McDaniel et al., "Idebenone: A new antioxidant - Part I. Relative assessment of oxidative stress protection capacity compared to commonly known antioxidants," J. Cosm. Dermatol., 4, No. 1, 10-17 (2005).
15. A. Merdente, G. Martorana, G. Minotti, and B. Giardina, "Antioxidant properties of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone (idebenone)," Chem. Res. Toxicol., 11, No. 1, 54-63 (1998).
16. T. Nabeshima, A. Nitta, K. Fuji, et al., "Oral administration of NGF synthesis stimulators recovers reduced brain NGF content in aged rats and cognitive dysfunction in basal-forebrain-lesioned rats," Gerontology (Basel), 40, Suppl. 2, 46-56 (1994).
17. A. Napolitano, "Long-term treatment with idebenone and riboflavin in a patient with MELAS," Neurol. Sci., 21, No. 5, Suppl., S981-S982 (2000).
18. G. Nappi, "Long-term idebenone treatment of vascular and degenerative brain disorders of the elderly," Arch. Gerontol. Geriatr., 15, No. 3, 261-269 (1992).
19. C. Scavini, A. Rozza, E. Lanza, et al., "Effect of idebenone on in vivo serotonin release and serotonergic receptors in young and aged rats," Eur. Neuropsychopharmacol., 6, 95-102 (1996).
20. I. Schols et al., "Therapeutic strategies in Friedreich's ataxia," J. Neurol. Transm., 68, Suppl., 135-145 (2004).
21. U. Senin, "Idebenone in senile dementia of Alzheimer type: A multi-centre study," Arch. Gerontol. Geriatr., 15, No. 3, 249-260 (1992).
22. Y. Sugiyama and T. Fujita, "Stimulation of respiratory and phosphorylating activities in rat brain mitochondria by idebenone (CV-2619), a new agent improving cerebral metabolism," FEBS Lett., 184, 48-51 (1985).
23. L. J. Thai et al., "Idebenone treatment fails to slow cognitive decline in Alzheimer's disease," Neurology, 61, No. 11, 1498-1502 (2003).
24. K. Yanagisawa "Natural progression of Alzheimer's disease (AD): A perspective on possible therapies for advanced AD," Rinsho Shinkeigaku, 44, No. 11, 921-923 (2004).